눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
NFPA 704
0
2
0
cangrelor테트라소듐 C화학적 특성, 용도, 생산
개요
Cangrelor
tetrasodium is a direct purinergic platelet receptor (P2Y12)
inhibitor that blocks ADP-induced platelet activation and
aggregation. The drug, which was developed by The
Medicine Company, binds reversibly to the P2Y12 receptor,
preventing further signaling and platelet activation. Cangrelor,
which was approved in June 2015 by the FDA, is indicated as
an adjunct to percutaneous coronary intervention for reducing
the risk of periprocedural myocardial infarction, repeat
coronary revascularization, and stent thrombosis in patients
who have not been treated with a P2Y12 platelet inhibitor and
are not being given a glycoprotein IIb/IIIa inhibitor. The
most common side effect observed with the drug was
bleeding.
용도
Antiplatelet agent.
정의
ChEBI: An organic sodium salt that is the tetrasodium salt of cangrelor. Used as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.
